Anti-EGFR chimeric antigen receptor T cell therapy - bluebird bio
Alternative Names: anti-EGFR CAR-T-bluebird bioLatest Information Update: 09 Jan 2023
At a glance
- Originator bluebird bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours